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Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses
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The interaction between infection and pediatric acute lymphoblastic leukemia (ALL) has been a focus of epidemiologic study for over 50 years. Although a protective effect against ALL has often been reported when surrogates of infection exposure, such as day care attendance, were analyzed, 1 studies of documented early infections indicated a subsequent increased risk of ALL. 2 A mechanistic explanation for these apparently contradictory findings has yet to be provided. The demonstration that a leukemia-initiating cell (LIC) for pediatric B-cell precursor (BCP) ALL frequently arises in utero has defined an extended pre-leukemic phase during which immune modulation could influence subsequent disease progression. [3] [4] [5] Consistent with this hypothesis, delayed exposure to multiple infections increased leukemia penetrance in Pax5 heterozygous mice. 6 A toll-like receptor (TLR) 4-driven upregulation of intrinsic mutagenic activity was proposed as a potential in vivo driver of this leukemogenesis, based on its contribution to the transformation of ETV6-RUNX1-transduced pre-B cells. 7 However, the potentially opposing impact of the induced immune response on the overall outcome of such inflammatory stimulation has not been evaluated. Here, we used the Eμ-ret 8, 9 and E2A-PBX1 10 transgenic mouse models of BCP ALL malignancy to investigate the influence of TLR ligation on LIC fate.
TLRs are important early sensors of infection and induce broad changes in the immune environment. 11 We have previously shown that TLR stimulation induces protective T-cell responses against fully transformed Eμ-ret leukemia cells in naive wild-type mice. 12 We now extend on that study by evaluating the effect of ligation of endosomal, nucleic acid-sensing TLRs on leukemia progression. An abnormal BCP population is detectable in bone marrow, spleen and peripheral blood of Eμ-ret mice months prior to disease onset based on its characteristic B220 int /BP-1 hi phenotype; 8, 9 this enables both purification of LIC for in vitro studies ( Figure 1a ), and correlation of quantitative changes in this cell population with disease progression in vivo. The leukemiainitiating potential of this BCP population is demonstrated by its progression to leukemia in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) recipient mice (data not shown). To evaluate for direct effects, abnormal BCP cells were purified from spleens of 4-week-old Eμ-ret mice and cultured in the presence of TLR ligands ( Figure 1b ). Both CpG ODN (TLR9 ligand) and R848 (TLR 7/8 ligand) caused a significant reduction in viable cell recovery, whereas polyI:C (TLR3 ligand) induced a significant expansion of the BCP population compared with the PBS-treated control. This finding is consistent with the ability of LPS to stimulate pre-leukemic cells, 7 but suggests that the nature of the response may be influenced by the specific TLR receptor that is engaged. To assess the impact of a concurrent immune response on these direct activities, bulk splenocyte cultures from 4-6-week-old Eμ-ret mice were similarly stimulated with TLR ligands (Figure 1b) . Notably, the presence of immune effector cells resulted in significant depletion of viable BCP by each TLR ligand (P o 0.0001 for each TLR ligand compared with its direct effects).
The impact of changes in their immune environment on LIC is likely to be influenced by their lineage and stage of differentiation arrest. Although, importantly, Eμ-ret mice consistently present with a leukemia arrested at the stage of B-cell differentiation observed most often in pediatric ALL, RET is not a recognized driver of clinical disease. This raises the possibility that the observed depletion may be specific for LIC generated by this oncogene. To address this directly, we compared effects on Eμ-retderived LIC to those achieved with LIC generated in a multistep ALL model driven by the clinically relevant E2A-PBX1 translocation ( Figure 1c ). 10 When cultured on NSG bone marrow, LIC from Eμ-ret and Tg(E2A-PBX1) Pax +/ − Cd19-Cre mice yielded a similar pattern of TLR-induced depletion. This result confirms the generality of the depletion response to distinct LIC populations and validates the Eμ-ret model for studies of immune influences on LIC survival and ALL progression.
The reduction in number of LIC achieved on NSG bone marrow implicated myeloid cells as an effector population. Endosomal TLR ligation in myeloid cells is a strong inducer of interferons (IFN) that can inhibit IL-7-driven BCP proliferation. 13 Thus, we evaluated the contribution of IFN to the BCP depletion activity and investigated whether it affected normal BCP. Bone marrow cells from Eμ-ret or wild-type mice showed similar levels of BCP depletion when stimulated with CpG ODN or R848, and this activity was significantly reduced in the presence of IFN type I-and II-blocking antibodies (Figure 1d ). Furthermore, in the absence of IFN activity, an expansion of BCP cells in response to Accepted article preview online 25 May 2016; advance online publication, 10 June 2016 polyI:C was achieved in both settings. The similar responses in wild-type and Eμ-ret cultures indicated that the TLR-induced activity targets BCP in general, rather than only the abnormal LIC. To evaluate if the activity of IFN was exerted directly on BCP, we exposed purified Eμ-ret-derived LIC to supernatant obtained from CpG ODN-or R848-stimulated BALB/c bone marrow cultures ( Figure 1e ). Such exposure was sufficient to achieve a depletion of similar magnitude to that observed in the presence of immune effector cells. For each TLR ligand, blockade of both type I and II IFN was necessary for maximal inhibition of BCP cell depletion, suggesting overlapping, direct inhibitory effects of IFN-α/β and IFN-γ on BCP cells. The depletion achieved in the presence of IFN-blocking antibodies was similar in magnitude to that resulting from direct activity, evaluated using supernatant from non-stimulated cells to which TLR ligand was added prior to incubation with BCP cells; this indicates that IFN activity accounts for most, if not all, the immune-mediated reduction in BCP cell number. To further evaluate the relevance of this immune pathway to human BCP ALL, we incubated ALL cell line RS4;11 and a primary ALL sample in media conditioned with supernatant from several human PBMC cultures stimulated with R848 or CpG ODN (Figure 1f ). IFN contributed significantly to the reduction in viable ALL cell recovery, though with more variability than was observed for LIC. An unexpected expansion of primary ALL cells was observed with CpG ODN-stimulated supernatant containing blocking antibodies from one donor, further emphasizing the variability in outcomes from such exposures.
Although informative, in vitro studies fail to capture the influence of specific microenvironments on immune activity and outcome. To confirm that a TLR-induced immune response could deplete abnormal BCP cells from an established pre-leukemic setting, we treated 4-week-old Eμ-ret mice with CpG ODN and then assessed LIC burden. At the completion of CpG ODN treatment, there was a significant reduction in the number of LIC in bone marrow and spleen of treated mice (Figure 2a ), indicating that neither the presence of intact stroma nor the regulatory pathways that are integral to a functional immune system impart protection from depletion. A dysregulated immune response to a common infection is often invoked in models of BCP ALL etiology. 14 (Figure 2b) . Notably, significantly less BCP cell depletion was achieved in the absence of IFN-γ, suggesting that alterations in downstream pathways can alter TLR-induced depletion activity. Finally, to investigate whether TLR-mediated depletion of early-occurring abnormal BCP cells was capable of altering the course of disease, we treated Eμ-ret mice with CpG ODN between 4 and 8 weeks of age and monitored for leukemia onset. A reduction of BCP cell burden in peripheral blood was achieved at the completion of the CpG ODN treatment (P o 0.05, data not shown), which correlated with a significant delay in disease onset in the treated group compared with control (median survival: 215 vs 152 days, P o 0.0001; Figure 2c ). Several mice remained disease-free beyond one year of age, suggesting that early-life immune response induction could reduce leukemia penetrance in this model.
This study reveals the sensitivity of leukemia-initiating BCP cells from two transgenic mouse models of BCP ALL to changes in immune environment, and is the first to report the impact of these changes on disease development. Our results provide support for the hypothesis that immune modulation during the pre-leukemic phase can significantly alter progression of BCP ALL and provide a feasible mechanistic link for the reported association of early-life infections with protection from ALL. Infections have been associated with both an increase and a decrease in BCP ALL risk; therefore, our study does not capture the full range of potential immune effects. When combined with the emerging evidence of leukemia-promoting immune activity, however, it does expose the complexity of variables that probably underlie these divergent outcomes: variables such as the recognition pathways engaged by the infectious agent, the context and extent of direct stimulation of LIC, and the immune responsiveness of the host, may all contribute to the overall effect. The ability of IFN neutralization to switch the outcome of TLR3 stimulation from pre-leukemic cell depletion to a potentially pro-leukemic proliferative signal, together with the inability to achieve BCP cell depletion in the absence of IFN-γ, underscore the importance of host immune responsiveness in determining outcome. Our study identifies type I and II IFN as in vivo modifiers of LIC fate that may significantly affect the impact of putative leukemia-driving activities such as the ETV6-RUNX1-mediated growth advantage in the presence of TGF-β and TLR4-upregulated mutagenic activity. 7, 15 Understanding the interactions between these pathways, immune system development and polymorphisms in immune response genes may reveal a unifying explanation for contrasting influences on BCP ALL risk that have been attributed to early-life infection. Myeloproliferative neoplasms (MPNs) are clonal neoplastic disorders of haematopoiesis, leading to a hypercellular bone marrow and eventually to severe fibrosis, termed myelofibrosis (MF). 1 Particularly advanced stage MF patients suffer from splenomegaly, anaemia and constitutional symptoms due to elevated levels of proinflammatory cytokines. A gain-of-function V617F mutation in the JAK2 kinase causes the constitutive activation of the JAK/STAT pathway and is supposed to be at least in part responsible for the disease phenotype of MPN. As the mutation is present in 65% of primary MF patients, 95% of polycythemia vera (PV) patients and 55% of essential thrombocythemia (ET) patients, various JAK inhibitors are currently tested as targeted therapeutics in MPN. 2 Ruxolitinib is an oral JAK inhibitor recently approved for treatment of primary and secondary MF that shows impressive symptom control by suppression of inflammation irrespective of the JAK mutational status. Moreover, ruxolitinib is also a promising drug for acute and chronic GvHD treatment. 3, 4 We recently described various aspects of immune modulation by ruxolitinib 5, 6 including impaired DC function. 7 Figure 1 . Ruxolitinib inhibits dendritic cell (DC) migration in vitro. (a) LPS-matured bmDCs (green) were added on the dermis of mice ventral ear sheets in the presence or absence of 1 μM ruxolitinib. Unbound cells were removed after 3 h, samples fixed and subsequently stained for laminin (red). Representative images of confocal microscopy from at least three independent experiments are depicted. (b, c) Ruxolitinibexposed human moDCs embedded in a three-dimensional collagen network were analysed for their migratory abilities towards CCL19. Migration patterns were followed by manual tracking of individual cells. Representative plots show 60 analysed cells per condition. Quantitative evaluations of migration parameters from three independent experiments are shown as scatter plots. Significance was tested using Mann-Whitney test U-test comparing samples with stimulated vehicle control ( ± s.e.m.; ***P o0.001). (d) Morphological analyses of human moDCs in the presence or absence of ruxolitinib were performed by immunofluorescence staining of the tubulin network (green) in LPS-matured moDCs seeded on fibronectin-coated slides. In addition, F-actin was labelled using phalloidin-TRITC (red) and DAPI was applied to visualize the nucleus (blue). Scale bar, 10 μM. (e) Migration of human moDCs in three-dimensional matrices was evaluated 120 h after talin1 knockdown. Quantification of velocity and accumulated distance from three individual experiments are shown. Parameters were compared with cells electroporated with control siRNA ( ± s.e.m.; n = 3; ***P o0.001). 
